Azevedo RS, Jen W-Y, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell/myeloid mixed phenotype acute leukemia. haematol [Internet]. 2025Dec.1 [cited 2025Dec.5];110(12):3129-32. Available from: https://haematologica.org/article/view/12143